Media Articles Related to Exelon (Rivastigmine)
Epilepsy drug could help treat Alzheimer's disease
Source: Epilepsy News From Medical News Today [2015.05.11]
University of British Columbia researchers say a new epilepsy drug holds promise as a treatment for Alzheimer's disease.
Alzheimer's Disease - Test Your Medical IQ
Source: MedicineNet Advance Medical Directives Specialty [2015.03.23]
Title: Alzheimer's Disease - Test Your Medical IQ
Category: MedicineNet Quiz
Created: 2/2/2012 5:35:00 PM
Last Editorial Review: 3/23/2015 4:01:03 PM
Source: MedicineNet Advance Medical Directives Specialty [2015.03.20]
Title: Alzheimer's Disease
Category: Diseases and Conditions
Created: 8/26/2008 12:00:00 AM
Last Editorial Review: 3/20/2015 12:00:00 AM
Drug restores brain function and memory in early Alzheimer's disease
Source: Epilepsy News From Medical News Today [2015.03.13]
A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer's disease, researchers at Johns Hopkins University found.
Experts criticise 'inaccurate' view that B Vitamins have no role in Alzheimer's disease prevention
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2015.02.23]
Patients in the very early stages of dementia could miss out on a potentially effective treatment after misleading research was published last year, say medical experts.
Published Studies Related to Exelon (Rivastigmine)
The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase
II, randomised, double blind, placebo controlled trial to evaluate the effect of
rivastigmine on gait in patients with Parkinson's disease who have fallen. 
BACKGROUND: Gait impairment is common in people with Parkinson's disease. There
is a lack of effective interventions to target this debilitating complication and
therefore a need to identify new therapeutic options... If effective, it would offer a new therapeutic option to ameliorating
gait and cognitive deficits in a population at high risk of falls.
Rivastigmine as alternative treatment for refractory REM behavior disorder in
Parkinson's disease. 
disease in whom conventional therapy failed... CONCLUSIONS: The results of this pilot trial need to be confirmed by further
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. [2011.12]
OBJECTIVES: The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of dementia at baseline... CONCLUSIONS: Rivastigmine benefits AD patients across dementia stages. Similar to previous cholinesterase inhibitor studies, greatest treatment effects with rivastigmine patch and capsule were seen in patients with more advanced dementia, most likely driven by greater placebo decline in this population. Copyright (c) 2010 John Wiley & Sons, Ltd. Copyright (c) 2010 John Wiley & Sons, Ltd.
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. [2011.07]
CONCLUSION: There were no significant differences in tolerability and safety between the treatment groups. The combination therapy of memantine plus rivastigmine patch did not show an advantage over rivastigmine patch monotherapy on efficacy analyses. The sample size for comparing tolerability may have been too small to detect a difference of efficacy between the two groups.
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. [2011.04]
OBJECTIVE: In Alzheimer's disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items... CONCLUSIONS: These findings suggest that rivastigmine may benefit specific ADL, particularly in patients who are already exhibiting functional impairment. Further research is required to improve understanding of how drugs such as rivastigmine exert their clinical effects. Copyright (c) 2010 John Wiley & Sons, Ltd.
Clinical Trials Related to Exelon (Rivastigmine)
A Double-Blind, Placebo-Controlled Crossover Study of Repeat Rivastigmine (Exelonï¿½) Administration in Young Healthy Male Volunteers [Not yet recruiting]
Rivastigmine is a carbamate, approved by the FDA for the treatment of mild to moderate
dementia associated with Alzheimer's and Parkinson's diseases. Studies conducted in the
Israel Institute of Biological Research (IIBR) have yielded encouraging results in utilizing
rivastigmine pre-treatment as an alternative to pyridostigmine in partially protecting
against organophosphate poisoning, particularly protecting the central nervous system.
The target population for this indication may consist of otherwise healthy people (e. g.
soldiers). Although the treatment regimen has not been established yet it is assumed, based
on animal experiments, that rivastigmine is likely to be administered in repeated doses. In
this setting, further evaluation of the drug's effects and pharmacokinetics in young healthy
subjects is warranted.
The objectives of this study are: 1) To assess the safety and tolerability of repeated
rivastigmine administration (1. 5 mg and 3 mg) in young healthy male volunteers; 2) To
determine the pharmacokinetic profile of rivastigmine (1. 5 mg and 3 mg) following a single
and multiple dose administrations; 3) To assess the extent of blood ChE inhibition following
a single and multiple administrations of rivastigmine and 4) To correlate physiological and
behavioral effects with blood rivastigmine concentrations and blood ChE inhibition in these
This double-blind, placebo-controlled study will be divided in 3 identical periods, preceded
with a two-day initial training in performing cognitive performance tests. Each period will
consist of in-house confinement for 5 days in which rivastigmine will be administered 5
times at an interval of 12 hours. During each period, each subject will receive either
rivastigmine 1. 5 mg X 5, or either rivastigmine 3. 0 mg X 5 or placebo X 5. The treatment in
each period will be randomly assigned in a crossover manner. Rivastigmine pharmacokinetics
will and acetylcholinesterase inhibition will be assessed after the first and the last dose
of each period and will be correlated with physiological and cognitive parameters:
performance tests, visual functions, peak airway flow, saliva production (sialometry) and
The emergence of adverse events will be monitored throughout the study
Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients [Recruiting]
The purpose of this study is to determine whether a exercise program when combined with
rivastigmine (Exelon patch) drug treatment compared with rivastigmine drug treatment alone
would improve quality of life, ability to perform activities of daily living (ADL) and
cognition in patients with Alzheimer's disease.
Ho: Rivastigmine drug treatment combined with exercise is not superior to rivastigmine drug
treatment to improve quality of life of alzheimer's disease patients.
H1: Rivastigmine drug treatment combined with exercise is superior to rivastigmine drug
treatment to improve quality of life of alzheimer's disease patients, with an expectative of
15% of improvement in the quality of life scale measurement
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease [Recruiting]
This study is designed to evaluate caregiver preference for Exelon® patch (target patch size
10 cm²) treatment in patients with Alzheimer's disease (MMSE 10-26) who were under
cholinesterase inhibitor treatment and experienced adverse event/s in a community setting.
Rivastigmine Prophylaxis in Elderly Patients Undergoing Major Surgery [Recruiting]
The purpose of this study is to determine whether preoperative administration of
Rivastigmine prevents the incidence of postoperative delirium in patients undergoing major
surgery as well as postoperative cognitive dysfunction.
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment [Recruiting]
This study will evaluate the efficacy and safety of 10 cm² rivastigmine patch vs. placebo
in cognitively impaired Multiple Sclerosis (MS) patients. Primary objective is the
assessment of cognition by the Selective Reminding Test (SRT) - a subtest of the brief
repeatable battery (BRB) - after titration of 4 weeks and maintenance of 12 weeks. This
double-blind period will be followed by a 52-week open-label treatment phase to assess
long-term safety of rivastigmine patch in these patients.
Reports of Suspected Exelon (Rivastigmine) Side Effects
Cerebrovascular Accident (69),
Dementia Alzheimer's Type (63),
Confusional State (57), more >>